Does CalViva Health require prior authorization for 83518?

CalViva Health lists 83518 on CalViva Health CMS-0057-F prior authorization requirements for medicaid managed plans (list dated December 31, 2025). Verify with the payer before scheduling.

Does Community Health Plan of Imperial Valley require prior authorization for 83518?

Community Health Plan of Imperial Valley lists 83518 on Community Health Plan of Imperial Valley CMS-0057-F prior authorization requirements for medicaid managed plans (list dated December 31, 2025). Verify with the payer before scheduling.

What insurance policy changes affect CPT 83518?

There are 6 tracked policy changes affecting CPT 83518, including updates from Independence Blue Cross, Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 83518?

Payers that have issued tracked updates for CPT 83518 include: Independence Blue Cross, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when CPT 83518 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 83518. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for CPT 83518?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

83518 Insurance Policy Changes

CPT 83518 is referenced in 6 tracked payer policy changes from Independence Blue Cross, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 83518 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Independence Blue Cross · Effective Oct 1, 2025Medium impact
MA08.029d, Natalizumab (Tysabri®) and Related Biosimilars
Independence Blue Cross reissued MA08.029d with no substantive coverage changes to the natalizumab (Tysabri) and biosimilar policy. However, ICD-10 diagnosis codes were refined: the broad code G35 (Multiple sclerosis) was replaced with three specific codes (G35.A, G35.C1, G35.D) to align with current MS classification. Billing teams must update diagnosis code mapping to ensure claims use the new specific codes rather than the removed general code.
Independence Blue Cross · Effective Oct 1, 2025Medium impact
08.00.64i, Natalizumab (Tysabri®) and Related Biosimilars
Independence Blue Cross reissued Policy 08.00.64i (Natalizumab/Tysabri and biosimilars) with updated ICD-10 diagnosis codes effective 10/01/2025. The policy replaced the broad 'G35 Multiple sclerosis' code with three specific codes (G35.A, G35.C1, G35.D) and added HCPCS code Q5134 for the biosimilar natalizumab-sztn (Tyruko). Medical necessity criteria remain substantially unchanged but now explicitly cover highly active relapsing MS, active secondary progressive MS, and Crohn's disease per updated FDA labeling.
Aetna · Identified Aug 17, 2026Medium impact
Fetal Fibronectin, Inflammatory Biomarkers, and Salivary Hormone Testing for Preterm Labor (CPB 0166, reviewed 2026-04-21)
Aetna considers the fetal fibronectin (fFN) immunoassay medically necessary to evaluate pregnant women with symptoms of preterm labor who are considered high-risk for preterm delivery when amniotic membranes are intact, cervical dilation is less than 3 cm, sampling occurs no earlier than 24 weeks 0 days and no later than 34 weeks 6 days of gestation, and results will be available quickly enough to influence real-time decisions for suspected preterm labor. A repeat fFN immunoassay is medically necessary when the member meets all of the same criteria and remains symptomatic 2 or more weeks after a previous negative fFN immunoassay. Fetal fibronectin testing for routine screening of the general obstetric population, for asymptomatic high-risk women, for identifying optimal cerclage candidates, and following cervical cerclage insertion is experimental, investigational or unproven, as are the biomarker, inflammatory marker, proteomic, metabolomic and salivary hormone tests named for preterm birth prediction.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Allergy Tests of Uncertain Efficacy
Allergy tests of uncertain efficacy are considered investigational because the scientific evidence does not permit conclusions regarding their effects on health outcomes. The listed investigational tests are ALCAT automated food testing, applied kinesiology, conjunctival challenge testing, cytotoxic food tests, electrodermal testing, hair analysis, IgG/IgG4 allergen specific antibody and food tests, iridology, leukocyte histamine release testing, nasal challenge testing, passive transfer (P-X) testing, provocation-neutralization food or food additive testing, and Rebuck skin window testing. Investigational services are not considered medically necessary, and the payer makes no payment for services that are not documented to be medically necessary.
Independence Blue Cross · Effective Oct 1, 2025Low impact
MA08.029d, Natalizumab (Tysabri®) and Related Biosimilars
Independence Blue Cross Medicare Advantage reissued policy MA08.029d for natalizumab (Tysabri) and related biosimilars effective 10/01/2025 with no substantive coverage changes. Three ICD-10 codes were updated to provide more specific multiple sclerosis diagnoses (G35.A, G35.C1, G35.D replacing general G35), which may affect claim coding accuracy but do not change medical necessity criteria or billing requirements.
Independence Blue Cross · Effective Oct 1, 2025Low impact
08.00.64i, Natalizumab (Tysabri®) and Related Biosimilars
Independence Blue Cross reissued policy 08.00.64i for natalizumab (Tysabri) and biosimilar natalizumab-sztn (Tyruko) with updated ICD-10 diagnosis codes. Three MS-related codes were added (G35.A, G35.C1, G35.D) and one generic code (G35) was removed. Medical necessity criteria remain substantively unchanged. The policy covers MS relapsing forms and Crohn's disease with existing approval requirements.

Watch 83518

Get one email when a payer policy names 83518, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

See every payer rule for 83518

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 83518 in one place.

See every payer rule

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

MA08.029d, Natalizumab (Tysabri®) and Related Biosimilars

08.00.64i, Natalizumab (Tysabri®) and Related Biosimilars

Fetal Fibronectin, Inflammatory Biomarkers, and Salivary Hormone Testing for Preterm Labor (CPB 0166, reviewed 2026-04-21)

Allergy Tests of Uncertain Efficacy